Cramer says Vertex has a drug that may address the ‘largest market opportunity in the world'

  • 📰 NBCNewYork
  • ⏱ Reading Time:
  • 32 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 16%
  • Publisher: 63%

Österreich Nachrichten Nachrichten

Österreich Neuesten Nachrichten,Österreich Schlagzeilen

CNBC’s Jim Cramer said investors keep an eye on Vertex Pharmaceuticals (VRTX) as the company develops a non-opioid pain drug.

"The biggest pharmacy issue how do we get pain removed, or at least nullified, without opiates? They have a plan — Vertex," Cramer said onunderway for the pain drug, known as VX-548. Vertex has said its goal is to create a new class of prescription medications that relieve pain and address the shortcomings of opioids, namely their addictive potential.

"I do believe that if they have something, it would be the largest market opportunity in the world," Cramer said, adding that late-stage study results for VX-548 are expected"within the year."In a note to clients Monday, analysts at Leerink Partners argued that the investment community significantly underappreciates" the potential for VX-548.

San Francisco quarterback Brock Purdy makes nearly $1 million a year — but splits rent with a roommate and drives a Toyota SUV31-year-old teacher quit her job. Now she works at Costco—and boosted her income by 50%: ‘I've never been happier'

Wir haben diese Nachrichten zusammengefasst, damit Sie sie schnell lesen können. Wenn Sie sich für die Nachrichten interessieren, können Sie den vollständigen Text hier lesen. Weiterlesen:

 /  🏆 270. in AT
 

Vielen Dank für Ihren Kommentar.Ihr Kommentar wird nach Prüfung veröffentlicht.

Österreich Neuesten Nachrichten, Österreich Schlagzeilen

Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.

Jim Cramer's top 10 things to watch in the stock market MondayThe Dow, S&P 500 and Nasdaq were lower Monday after Hamas conducted a surprise attack on Israel.
Herkunft: CNBC - 🏆 12. / 72 Weiterlesen »